Research Progress of Abnormal Expression of LKB1/STK111 in Non-Small Cell Lung Cancer

  • Fengmei Cao Shaanxi University of Chinese Medicine
  • Jiayun Liu Xijing Hospital, Forth Military Medical University
DOI: https://doi.org/10.18686/aem.v12i1.315
Keywords: LKB1/STK111, Non Small Cell Lung Cancer, Tumor Suppressive Mechanism, Prognosis, Treatment

Abstract

Non small cell lung cancer (NSCLC) is a kind of malignant tumor originated from bronchial mucosa, bronchial glands and alveolar epithelium. It has become the main cause of death of malignant tumors in our population. STK11 is a common tumor suppressor gene, its encoded protein liver kinase B1 (LKB1) is an essential serine / threonine protein kinase. LKB1/STK111 inhibits the occurrence and development of tumors through a variety of mechanisms and plays a key regulatory role in malignant tumors. The increased risk of cancer development is also associated with the absence of STK11. More and more studies have found that the abnormal expression of LKB1/STK111 will affect the occurrence and development of lung cancer, especially in NSCLC. This paper reviews the tumor suppressive mechanism of LKB1/STK111 in the occurrence and development of NSCLC, its relationship with NSCLC, and the prognosis and treatment.

References

[1] Agalioti T, Giannou A, Stathopoulos G. Pleural involvement in lung cancer[J]. Journal of thoracic disease, 2015, 7(6): 1021-30.

[2] Zhang Y, Meng Q, Sun Q, et al. LKB1 deficiency-induced metabolic reprogramming in tumorigenesis and non-neoplastic diseases[J]. Molecular metabolism, 2021, 44: 101131.

[3] Pons-Tostivint E, Lugat A, Fontenau J, et al. STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact[J]. Cells, 2021, 10(11).

[4] Adderley H, Blackhall F, Lindsay C. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition[J]. EBioMedicine, 2019, 41: 711-716.

[5] Lindsay C, Jamal-Hanjani M, Forster M, et al. KRAS: Reasons for optimism in lung cancer[J]. European journal of cancer (Oxford, England : 1990), 2018, 99: 20-27.

[6] Sumbly V, Landry I. Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer[J]. Cureus, 2022, 14(1): e21078.

[7] Arbour K, Riely G. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review[J]. JAMA, 2019, 322(8): 764-774.

[8] Ndembe G, Intini I, Perin E, et al. LKB1: Can We Target an Hidden Target? Focus on NSCLC[J]. Frontiers in oncology, 2022, 12: 889826.

[9] Rosellini P, Amintas S, Caumont C, et al. Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer[J]. European journal of cancer (Oxford, England : 1990), 2022, 172: 85-95.

[10] Best S, Gubser P, Sethumadhavan S, et al. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer[J]. Cell metabolism, 2022, 34(6): 874-887.e6.

[11] Devarakonda S, Pellini B, Verghese L, et al. TSC1, TSC2, NF1, NF2A phase II study of everolimus in patients with advanced solid malignancies with or mutations[J]. Journal of thoracic disease, 2021, 13(7): 4054-4062.
Published
2023-03-21
Issue
Vol 12, No 1(2023)
Section
Original Research Article

Copyright (c) 2023 Fengmei Cao

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.